Program
KNT-0916
A development code.
Its studies are led by KinoTeck Therapeutics.
Furthest: phase 1, since Jan 20, 20251 company-led study, 1 open or runningNext primary completion: Sep 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| KinoTeck Therapeutics | 11 open or running | phase 1since Jan 20, 2025 | Jan 20, 2025 | Sep 30, 2027phase 1 · NCT06800196 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2025First study: phase 1 study in Solid Tumors With FGFR2 Alterations, AdultFirst studyNCT06800196 · 151 planned · China
Ahead
- Sep 30, 2027Primary completion: phase 1 study in Solid Tumors With FGFR2 Alterations, AdultNCT06800196
TargetBeta
FGFR2 →read by rule
“• KNT-0916 is an oral inhibitor of FGFR2.”study text, by rule · the study
Other programs on FGFR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| lirafugratinibrule | elevar-therapeutics | phase 2 | 2 |
| FGFR2/3 Inhibitor CGT4859rule | cogent-biosciences-inc | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06800196Solid Tumors With FGFR2 Alterations, Adult · China | 1 | Recruiting | Sep 30, 2027 | 151 |
How it is read
Names in the registry
- “KNT-0916”, 1 entry
Codes read as this program: KNT0916.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.